Best clinical response and Deauville 5-point scale
| . | All treated patients, N = 91 . | |
|---|---|---|
| n (%) . | 95% CI . | |
| Objective response rate (CR + PR) | 77 (85) | 75.5, 91.3 |
| CMR/CR | 61 (67) | 56.4, 76.5 |
| Deauville score = 1 | 23 (25) | |
| Deauville score = 2 | 20 (22) | |
| Deauville score = 3 | 12 (13) | |
| Deauville score = 4* | 2 (2) | |
| Deauville score = 5* | 4 (4) | |
| PMR/PR | 16 (18) | 10.4, 27 |
| Deauville score = 4 | 9 (10) | |
| Deauville score = 5 | 7 (8) | |
| NMR/SD | 5 (5) | 1.8, 12.4 |
| Deauville score = 4 | 1 (1) | |
| Deauville score = 5 | 4 (4) | |
| PMD/PD | 7 (8) | 3.1, 15.2 |
| Deauville score = 5 | 7 (8) | |
| Not evaluable | 1 (1) | |
| Not applicable† | 1 (1) | |
| . | All treated patients, N = 91 . | |
|---|---|---|
| n (%) . | 95% CI . | |
| Objective response rate (CR + PR) | 77 (85) | 75.5, 91.3 |
| CMR/CR | 61 (67) | 56.4, 76.5 |
| Deauville score = 1 | 23 (25) | |
| Deauville score = 2 | 20 (22) | |
| Deauville score = 3 | 12 (13) | |
| Deauville score = 4* | 2 (2) | |
| Deauville score = 5* | 4 (4) | |
| PMR/PR | 16 (18) | 10.4, 27 |
| Deauville score = 4 | 9 (10) | |
| Deauville score = 5 | 7 (8) | |
| NMR/SD | 5 (5) | 1.8, 12.4 |
| Deauville score = 4 | 1 (1) | |
| Deauville score = 5 | 4 (4) | |
| PMD/PD | 7 (8) | 3.1, 15.2 |
| Deauville score = 5 | 7 (8) | |
| Not evaluable | 1 (1) | |
| Not applicable† | 1 (1) | |
CMR/CR, PMR/PR, NMR/SD, and PMD/PD per Lugano classification 2014,17 with PET scan assessment required to determine response. CMR/CR, PMR/PR, NMR/SD, PMD/PD, CP, and not evaluable are mutually exclusive. Patients with both PMD/PD and clinical progression are counted as PMD/PD.
CMR, complete metabolic response; NMR, no metabolic response; PMD, progressive metabolic disease; PMR, partial metabolic response; PR, partial response; SD, stable disease.
Five patients in part 3 with CR met LYRIC criteria for IR-2 (4 with negative biopsies; 1 false positive with no corresponding lesion on CT scan). One patient in part 1/2 had a residual FDG-avid lesion (Deauville score of 5) following study treatment but was considered CR because a biopsy showed no evidence of HL.
No postbaseline assessment.